Comparing Clinical Presentations, Treatments and Outcomes of Hepatocellular Carcinoma Due to Hepatitis C and Non-alcoholic Fatty Liver Disease

Overview

Journal QJM

Specialty General Medicine

Date 2016 Sep 17

PMID 27634970

Citations 22

Authors

Nwe Ni Than

Anwar Ghazanfar

James Hodson

Nadeem Tehami

Chris Coldham

Hynek Mergental

Derek Manas

Tahir Shah

Philip N Newsome

Helen Reeves

Shishir Shetty

Affiliations

Soon will be listed here.

Abstract

Introduction: Hepatocellular carcinoma (HCC) is increasing in incidence in the UK and globally. Liver cirrhosis is the common cause for developing HCC. The common reasons for liver cirrhosis are viral hepatitis C (HCV), viral hepatitis B and alcohol. However, HCC caused by non-alcoholic fatty liver disease (NAFLD)-cirrhosis is now increasingly as a result of rising worldwide obesity.

Aim: : To compare the clinical presentation, treatment options and outcomes of HCC due to HCV and NAFLD patients.

Methods: Data were collected from two liver transplant centres in the UK (Birmingham and Newcastle upon Tyne) between 2000 and 2014. We compared 275 patients with HCV-related HCC against 212 patients with NAFLD- related HCC.

Results: Patients in the NAFLD group were found to be significantly older ( P < 0.001) and more likely to be Caucasian ( P < 0.001). They had lower rates of cirrhosis ( P < 0.001) than those in HCV-HCC group. The NAFLD group presented with significantly larger tumours ( P = 0.009), whilst HCV patients had a higher alpha fetoprotein ( P = 0.018). NAFLD patients were more commonly treated with TACE ( P = 0.005) than the HCV patients, whilst the HCV group were significantly more likely to be transplanted ( P < 0.001). In patients selected for liver transplantation, 5-year survival rates in NAFLD were not significantly different from HCV-HCC (44 and 56% respectively, P = 0.102).

Conclusion: In this study, NAFLD patients presented with larger tumours that were less likely to be amenable to curative therapy, as compared with HCV patients. Despite this disadvantage, patients with NAFLD had similar overall survival compared to patients with HCV.

Citing Articles

Comparative evaluation of multimarker algorithms for early-stage HCC detection in multicenter prospective studies.

Hou J, Berg T, Vogel A, Piratvisuth T, Trojan J, De Toni E JHEP Rep. 2025; 7(2):101263.

PMID: 39897614 PMC: 11782856. DOI: 10.1016/j.jhepr.2024.101263.

Lower hepatocellular carcinoma surveillance in metabolic dysfunction-associated steatotic liver disease: Impact on treatment eligibility.

Henry-Blake C, Balachandrakumar V, Kassab M, Devonport J, Matthews C, Fox J J Gastroenterol Hepatol. 2024; 39(12):2817-2825.

PMID: 39191435 PMC: 11660197. DOI: 10.1111/jgh.16727.

British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.

Suddle A, Reeves H, Hubner R, Marshall A, Rowe I, Tiniakos D Gut. 2024; 73(8):1235-1268.

PMID: 38627031 PMC: 11287576. DOI: 10.1136/gutjnl-2023-331695.

Alpha-fetoprotein: Past, present, and future.

Yeo Y, Lee Y, Tseng H, Zhu Y, You S, Agopian V Hepatol Commun. 2024; 8(5).

PMID: 38619448 PMC: 11019827. DOI: 10.1097/HC9.0000000000000422.

MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges.

Phoolchund A, Khakoo S Cancers (Basel). 2024; 16(2).

PMID: 38254750 PMC: 10814413. DOI: 10.3390/cancers16020259.

References

Calle E, Rodriguez C, Walker-Thurmond K, Thun M . Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348(17):1625-38. DOI: 10.1056/NEJMoa021423. View

Moller H, Mellemgaard A, Lindvig K, Olsen J . Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer. 1994; 30A(3):344-50. DOI: 10.1016/0959-8049(94)90254-2. View

Petrick J, Freedman N, Demuth J, Yang B, Van Den Eeden S, Engel L . Obesity, diabetes, serum glucose, and risk of primary liver cancer by birth cohort, race/ethnicity, and sex: Multiphasic health checkup study. Cancer Epidemiol. 2016; 42:140-6. PMC: 4899157. DOI: 10.1016/j.canep.2016.04.009. View

Ermis F, Tasci E . New treatment strategies for hepatitis C infection. World J Hepatol. 2015; 7(17):2100-9. PMC: 4539403. DOI: 10.4254/wjh.v7.i17.2100. View

Bailly F, Pradat P, Virlogeux V, Zoulim F . Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis. Dig Dis. 2015; 33(4):613-23. DOI: 10.1159/000375359. View

Yang W, Va P, Bray F, Gao S, Gao J, Li H . The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies. PLoS One. 2011; 6(12):e27326. PMC: 3244388. DOI: 10.1371/journal.pone.0027326. View

Sanyal A, Poklepovic A, Moyneur E, Barghout V . Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin. 2010; 26(9):2183-91. DOI: 10.1185/03007995.2010.506375. View

Bhala N, Angulo P, van der Poorten D, Lee E, Hui J, Saracco G . The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011; 54(4):1208-16. PMC: 3238674. DOI: 10.1002/hep.24491. View

Davila J, Morgan R, Shaib Y, McGlynn K, El-Serag H . Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005; 54(4):533-9. PMC: 1774454. DOI: 10.1136/gut.2004.052167. View

10.

Ascha M, Hanouneh I, Lopez R, Tamimi T, Feldstein A, Zein N . The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010; 51(6):1972-8. DOI: 10.1002/hep.23527. View

11.

Angulo P . Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16):1221-31. DOI: 10.1056/NEJMra011775. View

12.

Tokushige K, Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N . Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol. 2010; 45(9):960-7. DOI: 10.1007/s00535-010-0237-1. View

13.

Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S . Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016; 65(4):719-726. DOI: 10.1016/j.jhep.2016.04.008. View

14.

Rahman R, Hammoud G, Almashhrawi A, Ahmed K, Ibdah J . Primary hepatocellular carcinoma and metabolic syndrome: An update. World J Gastrointest Oncol. 2013; 5(9):186-94. PMC: 3782682. DOI: 10.4251/wjgo.v5.i9.186. View

15.

Lam B, Jeffers T, Younoszai Z, Fazel Y, Younossi Z . The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol. 2015; 8(5):298-312. PMC: 4530432. DOI: 10.1177/1756283X15587481. View

16.

Sanyal A, Banas C, Sargeant C, Luketic V, Sterling R, Stravitz R . Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006; 43(4):682-9. DOI: 10.1002/hep.21103. View

17.

El-Serag H, Tran T, Everhart J . Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004; 126(2):460-8. DOI: 10.1053/j.gastro.2003.10.065. View

18.

Starley B, Calcagno C, Harrison S . Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010; 51(5):1820-32. DOI: 10.1002/hep.23594. View

19.

Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves H . Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2014; 33(6):550-8. PMC: 4322258. DOI: 10.1200/JCO.2014.57.9151. View

20.

Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin J, Fraumeni J . A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control. 2001; 12(1):13-21. DOI: 10.1023/a:1008995217664. View